Table 7.
Baseline and treatment-planning factors independently associated with clinically significant weight loss during radiotherapy.
| Predictor | Adjusted OR | 95% CI | p-value |
|---|---|---|---|
| Age ≥70 years | 1.16 | 0.80–1.68 | 0.44 |
| Male sex | 1.12 | 0.79–1.58 | 0.53 |
| Baseline BMI < 18.5 kg/m2 | 1.68 | 1.04–2.72 | 0.03 |
| Pre-treatment weight loss ≥5% | 2.41 | 1.63–3.57 | <0.001 |
| Cancer stage: Stage I–II | Reference | – | – |
| Stage III vs. Stage I–II | 1.63 | 1.15–2.32 | 0.006 |
| Stage IV vs. Stage I–II | 1.91 | 1.23–2.97 | 0.004 |
| Baseline PNI < 45 | 1.74 | 1.22–2.48 | 0.002 |
| Head and neck cancer | 2.16 | 1.42–3.28 | <0.001 |
| Upper gastrointestinal cancer | 1.79 | 1.12–2.87 | 0.02 |
| Planned concurrent chemotherapy | 1.92 | 1.34–2.75 | <0.001 |